WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318984

CAS#: 137234-62-9

Description: Voriconazole is a triazole antifungal medication that is generally used to treat serious, invasive fungal infections. Voriconazole has also been proven effective against a number of other serious fungal pathogens. This includes infections by Fusarium spp and Scedosporium apiospermum (asexual form of Pseudallescheria boydii). Although infrequently seen, these molds are emerging as more common and deadly causes of fungal infection in seriously immunocompromised patients, and the development of voriconazole has been an important advance in their treatment as they are generally resistant to other antifungal agents (including amphotericin B). Voriconazole is the first and only drug ever specifically indicated for their treatment by the FDA. Voriconazole has also been used to treat severe fungal corneal infection.

Chemical Structure

CAS# 137234-62-9

Theoretical Analysis

MedKoo Cat#: 318984
Name: Voriconazole
CAS#: 137234-62-9
Chemical Formula: C16H14F3N5O
Exact Mass: 349.11504
Molecular Weight: 349.31721
Elemental Analysis: C, 55.01; H, 4.04; F, 16.32; N, 20.05; O, 4.58

Price and Availability

Size Price Availability Quantity
25.0mg USD 150.0 2 Weeks
50.0mg USD 250.0 2 Weeks
100.0mg USD 400.0 2 Weeks
200.0mg USD 650.0 2 Weeks
500.0mg USD 950.0 2 Weeks
1.0g USD 1650.0 2 Weeks
Bulk inquiry

Synonym: UK-109496; UK 109496; UK109496; UK109,496; UK-109,496; UK 109,496; Voriconazole; Vfend

IUPAC/Chemical Name: (2R,3S)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol


InChi Code: InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

SMILES Code: C[C@@H](C1=NC=NC=C1F)[C@@](O)(C2=CC=C(F)C=C2F)CN3N=CN=C3

Appearance: White to light yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 349.31721 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Turner RB, Martello JL, Malhotra A. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: A systematic review. Int J Antimicrob Agents. 2015 Oct;46(4):362-6. doi: 10.1016/j.ijantimicag.2015.05.023. Epub 2015 Jul 22. Review. PubMed PMID: 26253129.

2: Karthaus M, Lehrnbecher T, Lipp HP, Kluge S, Buchheidt D. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach. Ann Hematol. 2015 Apr;94(4):547-56. doi: 10.1007/s00277-015-2333-z. Epub 2015 Feb 20. Review. PubMed PMID: 25697592.

3: Gomulka J, Wilson BD, Joyce JC. Toxic epidermal necrolysis due to voriconazole: case report and review. Dermatol Online J. 2014 Sep 16;20(9). pii: 13030/qt2pt32578. Review. PubMed PMID: 25244163.

4: Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 2014 Sep;44(3):183-93. doi: 10.1016/j.ijantimicag.2014.05.019. Epub 2014 Jul 7. Review. PubMed PMID: 25106074.

5: Ho HC, Hsiao SH, Lee CY, Tsai CC. Treatment of refractory Aspergillus otomycosis with voriconazole: case series and review. J Laryngol Otol. 2014 Jun;128(6):547-51. doi: 10.1017/S0022215114001273. Epub 2014 Jun 9. Review. PubMed PMID: 24909800.

6: Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database Syst Rev. 2014 Feb 24;2:CD004707. doi: 10.1002/14651858.CD004707.pub3. Review. PubMed PMID: 24563222.

7: Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, Johnson JA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy. 2014 Jul;34(7):703-18. doi: 10.1002/phar.1400. Epub 2014 Feb 7. Review. PubMed PMID: 24510446; PubMed Central PMCID: PMC4082739.

8: Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014 Apr;58(7):997-1002. doi: 10.1093/cid/cit940. Epub 2013 Dec 20. Review. PubMed PMID: 24363331.

9: Holle J, Leichsenring M, Meissner PE. Nebulized voriconazole in infections with Scedosporium apiospermum--case report and review of the literature. J Cyst Fibros. 2014 Jul;13(4):400-2. doi: 10.1016/j.jcf.2013.10.014. Epub 2013 Nov 18. Review. PubMed PMID: 24263169.

10: Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJ. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther. 2013 Sep;11(9):931-41. doi: 10.1586/14787210.2013.826989. Review. PubMed PMID: 24053274.

11: Tedja R, El-Sherief A, Olbrych T, Gordon S. Multifocal periostitis as a complication of chronic use of voriconazole in a lung transplant recipient. Transpl Infect Dis. 2013 Aug;15(4):424-9. doi: 10.1111/tid.12088. Epub 2013 May 13. Review. PubMed PMID: 23663268.

12: Inano S, Kimura M, Iida J, Arima N. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review. J Infect Chemother. 2013 Dec;19(6):1173-80. doi: 10.1007/s10156-013-0594-9. Epub 2013 Apr 6. Review. PubMed PMID: 23564310.

13: Oliveira Fde M, Unis G, Hochhegger B, Severo LC. Scedosporium apiospermum eumycetoma successfully treated with oral voriconazole: report of a case and review of the Brazilian reports on scedosporiosis. Rev Inst Med Trop Sao Paulo. 2013 Mar-Apr;55(2):121-3. Review. PubMed PMID: 23563766.

14: Sayah DM, Schwartz BS, Kukreja J, Singer JP, Golden JA, Leard LE. Scedosporium prolificans pericarditis and mycotic aortic aneurysm in a lung transplant recipient receiving voriconazole prophylaxis. Transpl Infect Dis. 2013 Apr;15(2):E70-4. doi: 10.1111/tid.12056. Epub 2013 Feb 6. Review. PubMed PMID: 23387799.

15: Rimawi RH, Carter Y, Ware T, Christie J, Siraj D. Use of voriconazole for the treatment of Paecilomyces lilacinus cutaneous infections: case presentation and review of published literature. Mycopathologia. 2013 Apr;175(3-4):345-9. doi: 10.1007/s11046-012-9610-3. Epub 2013 Jan 20. Review. PubMed PMID: 23334554.

16: Davies-Vorbrodt S, Ito JI, Tegtmeier BR, Dadwal SS, Kriengkauykiat J. Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review. Pharmacotherapy. 2013 Jan;33(1):22-30. doi: 10.1002/phar.1156. Review. PubMed PMID: 23307541.

17: Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmenia C, Micozzi A, Sanguinetti M, Viscoli C. Voriconazole in clinical practice. J Chemother. 2012 Dec;24(6):311-27. doi: 10.1179/1973947812Y.0000000051. Review. PubMed PMID: 23174096.

18: Cherian T, Giakoustidis A, Yokoyama S, Heneghan M, O'Grady J, Rela M, Wendon J, Heaton DN, Verma A. Treatment of refractory cerebral aspergillosis in a liver transplant recipient with voriconazole: case report and review of the literature. Exp Clin Transplant. 2012 Oct;10(5):482-6. Review. PubMed PMID: 23031086.

19: Watt K, Manzoni P, Cohen-Wolkowiez M, Rizzollo S, Boano E, Jacqz-Aigrain E, Benjamin DK. Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab. 2013 Feb;14(2):193-202. Review. PubMed PMID: 22935068; PubMed Central PMCID: PMC3541435.

20: Keshtkar-Jahromi M, McTighe AH, Segalman KA, Fothergill AW, Campbell WN. Unusual case of cutaneous and synovial Paecilomyces lilacinus infection of hand successfully treated with voriconazole and review of published literature. Mycopathologia. 2012 Sep;174(3):255-8. doi: 10.1007/s11046-012-9540-0. Epub 2012 Apr 8. Review. PubMed PMID: 22484831.